[Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].
OBJECTIVE
The objectives of our study were to assess frequency, severity and outcome of renal abnormalities, as well as to determine the risk of developing hypophosphataemia in HIV-infected patients receiving tenofovir.


METHODS
An observational study was conducted in real-life conditions, during a 6-month period, in 107 HIV patients receiving tenofovir.


RESULTS
Mild-to-moderate hypophosphataemia (<0.77 mmol/L) occurred during follow-up, at least once in 43% of patients and at least twice in 27%. Antiretroviral therapy including ritonavir + lopinavir was significantly associated with the occurrence of hypophosphataemia (relative risk = 2.6; p = 0.03). Frequency of abnormal proteinuria was 22%.


CONCLUSIONS
Creatinine clearance, phosphataemia, proteinuria and glycosuria should be closely monitored in patients receiving tenofovir therapy.
Lochet
Pierre
P
Service des Maladies Infectieuses et Tropicales, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
Peyrière
Helène
H
Le Moing
Vincent
V
Blayac
Jean-Pierre
JP
Hansel
Sylvie
S
Reynes
Jacques
J
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir
D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine